AstraZeneca
🇬🇧United Kingdom
- Country
- 🇬🇧United Kingdom
- Ownership
- Public
- Employees
- 89.9K
- Market Cap
- $270.3B
- Website
- http://www.astrazeneca.co.uk
- Introduction
AstraZeneca Plc is a holding company, which engages in the research, development, manufacture, and commercialization of prescription medicines. The company was founded on June 17, 1992 and is headquartered in Cambridge, the United Kingdom.
DISCOVERY Asia - Crestor in Type IIa and IIb Hypercholesteremia
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-10-19
- Last Posted Date
- 2008-02-07
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1362
- Registration Number
- NCT00241488
A Study Evaluating the Efficacy and Safety of Adding Symlin® to Lantus® (Insulin Glargine) in Subjects With Type 2 Diabetes
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2015-03-31
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 200
- Registration Number
- NCT00240253
- Locations
- 🇺🇸
Research Site, Spokane, Washington, United States
Rosuvastatin Impact on Ventricular Remodelling Lipids and Cytokines
Phase 3
Completed
- Conditions
- Heart Failure, Congestive
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 160
- Registration Number
- NCT00240292
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
Study in High Risk Patients Switched From Higher Doses of Other Statins to Crestor on the Percentage of Patients Reaching the New LDL-C Target Goal
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-08-30
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2650
- Registration Number
- NCT00240344
- Locations
- 🇳🇱
Research Site, Zwolle, Netherlands
The Effect of Rosuvastatin on Aortic Stiffness in Hemodialysis Patients in the AURORA Study
Phase 3
Completed
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 10
- Registration Number
- NCT00240279
- Locations
- 🇳🇱
Research Site, Nieuwegein, Netherlands
A Study To Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden (ASTEROID)
Phase 3
Completed
- Conditions
- Coronary Arteriosclerosis
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 450
- Registration Number
- NCT00240318
- Locations
- 🇪🇸
Research Site, Valladolid, Spain
AURORA: Crestor 10mg Versus Placebo in Subjects With End-stage Renal Disease (ESRD)
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2011-05-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 2776
- Registration Number
- NCT00240331
- Locations
- 🇬🇧
Research Site, Surrey, United Kingdom
A Study to Investigate the Effect of Rosuvastatin (CRESTOR®) on High Density Lipoprotein Kinetics in Patients With the Metabolic Syndrome
Phase 3
Completed
- Conditions
- Metabolic SyndromeDyslipidemia
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2009-03-16
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240305
- Locations
- 🇦🇺
Research Site, Perth, Western Australia, Australia
Effect of an Internet Based Compliance Enhancement Tool in Subjects With Hypercholesterolemia
Phase 4
Withdrawn
- Conditions
- Hypercholesterolemia
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2009-03-26
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 1175
- Registration Number
- NCT00240357
- Locations
- 🇩🇰
Research Site, Ålestrup, Denmark
Study of High Density Lipoprotein Cholesterol (HDL-C)-Raising Mechanism of Rosuvastatin (CRESTOR™) by Quantifying the Key Steps of Reverse Cholesterol Transport (RCT)
Phase 3
Completed
- Conditions
- Metabolic SyndromeDyslipidemia
- First Posted Date
- 2005-10-18
- Last Posted Date
- 2010-11-19
- Lead Sponsor
- AstraZeneca
- Target Recruit Count
- 15
- Registration Number
- NCT00240266
- Locations
- 🇦🇺
Research Site, Melbourne, Victoria, Australia
© Copyright 2025. All Rights Reserved by MedPath